Business
MiNK Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results
Clinical update of allo-iNKTs (agenT-797) in solid tumors to be presented at AACR Annual Meeting in April 2023AgenT-797 in combination with pembro or nivo in
About this update from Mink Therapeutics, Inc.
[{"type":"text","content":"Clinical update of allo-iNKTs (agenT-797) in solid tumors to be presented at AACR Annual Meeting in April 2023AgenT-797 in combination with pembro or nivo in NSCLC and gastric cancer to initiate in 2023Allogeneic CAR platform demonstrates differentiation with IL-15-FAP-CAR-iNKT (MiNK-215) and IL-15-BCMA-CAR-iNKT (MiNK-413) in IND enabling studies NEW YORK, March 21, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today reported financial results for the fourth quarter and full year 2022. “2022 has been an important year for MiNK, with significant progress across our clinical and preclinical programs in iNKT cell therapy, bolstered by the expansion of our in-house manufacturing capabilities,\" stated Dr. Jennifer Buell, President and Chief Executive Officer of MiNK. \"Our advancements have solidified MiNK's position as a leader in the iNKT cell therapy field, with a growing body of clinical data demonstrating the potential of iNKT cells alone and in combination with standard of care agents, as well as novel insights into their unique mechanisms of action. Additionally, we've made strides in our CAR-iNKT program. As we move into 2023, we are eager to build on this momentum and rapidly expand our solid tumor program, leveraging our strong foundation to accelerate the development of potentially life-saving therapies for patients.\" Fourth Quarter and Full Year 2022 Business Highlights: MiNK's focus is on advancing the clinical and preclinical programs of their iNKT cell pipeline, as well as expanding their in-house manufacturing capabilities. Here are some key achievements and upcoming milestones for MiNK: Solid tumor cancers: AgenT-797, an allogeneic unmodified iNKT cell therapy, has shown clinical activity in solid tumor cancers (data presented at SITC 2022).AgenT-797 alone or in combination with approved anti-PD-1 (pembro or nivo) in advanced solid tumor cancers showed early signals of benefit without lymphodepletion; cells were tolerable to 1x109 cells/dose with no neurotoxicity or CRS.Updated data selected for presentation at the American Association for Cancer Research (AACR) on ...